| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Case Report |
| Article Title |
Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Apolonia Novillo, María Gaibar, Alicia Romero-Lorca, María Fuencisla Gilsanz, Laura Beltrán, Miguel Galán, Beatriz Antón, Diego Malón, Amalia Moreno and Ana Fernández-Santander |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Universidad Europea de Madrid |
2015/UEM12 |
|
| Corresponding Author |
Ana Fernández-Santander, PhD, Full Professor, Research Scientist, Senior Researcher, Department of Medicine, Health Sciences Faculty, Universidad Europea de Madrid, Tajo, Villaviciosa de Odón, Madrid 28670, Spain. ana.fernandez@universidadeuropea.es |
| Key Words |
Colorectal cancer; Bevacizumab; Chemokine CXCL5; Gene expression; Progression-free survival; Case report |
| Core Tip |
Although compared to chemotherapy (CT) alone, bevacizumab-containing CT leads to a significantly better tumor response in metastatic colorectal cancer patients, many do not benefit from this regimen probably due to resistance mechanisms or readjustment of proangiogenic pathways. While CXCL5 expression has been described to predict a poor prognosis in different cancers, its relationship with the efficacy of CT regimens has been scarcely addressed. Our three patients showing CXCL5 higher expression (6 times the levels recorded in the others) showed a poor response in terms of progression-free survival. Our observations provide direction for future studies designed to examine in metastatic colorectal cancer patients treated with bevacizumab-containing therapy, the possible association between CXCL5 gene overexpression and a poor response to treatment with angiogenic drugs. |
| Publish Date |
2020-04-28 08:04 |
| Citation |
Novillo A, Gaibar M, Romero-Lorca A, Gilsanz MF, Beltrán L, Galán M, Antón B, Malón D, Moreno A, Fernández-Santander A. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol 2020; 26(16): 1979-1986 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i16/1979.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i16.1979 |
